. 2022 Jul 14;195(1):1–15. doi: 10.1007/s10549-022-06665-6

Table 1.

Non-randomized clinical trials of immune checkpoint blockade with or without chemotherapy in metastatic TNBC

Trial	Key inclusion	Treatment	Subgroups	Sample size	ORR (%)	DCR (%)	Median DOR (months)	Median PFS (months)	Median OS (months)
NCT01772004^a	Any line	Avelumab		58	5.2	31	NR	5.9	9.2
JAVELIN Solid Tumor	Any line	Avelumab		58	5.2	31	NR	5.9	9.2
NCT01375842	Any line	Atezolizumab		115	10	13	21.0	1.4	8.9
			PD-L1 IC ≥ 1%	91	12	15	21.0	1.4	10.1
			PD-L1 IC < 1 %	21	0	5	N/A	1.4	6.0
NCT01848834	Any line	Pembrolizumab		32	18.5	25.9	NR	1.9	11.2
	PD-L1 IC/TC
	≥ 1%
KEYNOTE-012	≥ 1%
NCT02447003	≥ 2nd line	Pembrolizumab		170	5.3	7.6	NR	2.0	9.0
KEYNOTE-086
Cohort A
			PD-L1 CPS ≥ 1	105	5.7	9.5	NR	2.0	8.8
			PD-L1 CPS < 1	64	4.7	4.7	4.4	1.9	9.7
NCT02447003	1st line	Pembrolizumab		84	21.4	23.8	10.4	2.1	18.0
NCT02447003	PD-L1 CPS ≥ 1
KEYNOTE-086
Cohort B
NCT01633970	Any line	Atezolizumab +		33	39.4	51.5	9.1	5.5	14.7
		Nab-paclitaxel		33	39.4	51.5	9.1	5.5	14.7
			PD-L1 IC ≥ 1%	12	41.7	91.7	9.1	6.9	21.9
			PD-L1 IC < 1%	12	33.3	75.0	10.2	5.1	11.4
NCT02513472	1st line	Pembrolizumab + eribulin	PD-L1 CPS ≥ 1	29	34.5	NA	8.3	6.1	21.0
KEYNOTE-150			PD-L1 CPS ≥ 1	29	34.5	NA	8.3	6.1	21.0
			PD-L1 CPS < 1	31	16.1		15.2	3.5	15.2
	2nd or 3rd line		PD-L1 CPS ≥ 1	45	24.4	NA	8.2	4.1	14.0
	2nd or 3rd line		PD-L1 CPS < 1	44	18.2		8.6	3.9	15.5
NCT03044730^a	Any line	Pembrolizumab + capecitabine		15	13	60	NA	4.0	15.3
NCT03121352	1st or 2nd line	Pembrolizumab + carboplatin +		30	52	77.8	NA	6.1	11.5
NCT03121352	1st or 2nd line	Nab-paclitaxel		30	52	77.8	NA	6.1	11.5

ORR overall response rate, DCR disease control rate, DOR duration of response, PFS progression-free survival, OS overall survival, PD-L1 programmed death-ligand 1, IC immune cell, TC tumor cell, CPS combined positive score, NR not reached, NA not available

^aData from the TNBC subgroup of included patients is listed